Viatris/VTRS

$12.36

-1.82%
-
1D1W1MYTD1YMAX

About Viatris

Viatris Inc. (Viatris) is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, as well as the Company’s ARV franchise. Its portfolio comprises over 1,400 approved molecules across a range of key therapeutic areas, including key brands and complex generics. It operates around 40 manufacturing sites worldwide, which produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients. Its products include Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen Auto Injector, Fraxiparine and Yupelri.

Ticker

VTRS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Scott Smith

Employees

38,000

Headquarters

Canonsburg, United States

Viatris Metrics

BasicAdvanced
$14.95B
Market cap
297.43
P/E ratio
$0.04
EPS
1.14
Beta
$0.48
Dividend rate
3.81%
Dividend yield

What the Analysts think about Viatris

Analyst Ratings

Majority rating from 10 analysts.
Hold

Price Targets

Average projection from 8 analysts.
16.34% upside
High $35.00
Low $10.00
$12.36
Current price
$14.38
Average price target

Viatris Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-19.95% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$3.84B
-2.65%
Net income
$-765.6M
-330.88%
Profit margin
-19.95%
-337.22%

Viatris Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 4.12%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.77
$0.75
$0.79
$0.62
-
Expected
$0.69
$0.71
$0.74
$0.65
$0.71
Surprise
12.16%
5.59%
6.72%
-4.12%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Viatris stock

Buy or sell Viatris stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing